Combination therapy with the oral BCL-2 inhibitor venetoclax plus a hypomethylating agent demonstrated a tolerable safety profile in elderly patients with untreated acute myeloid leukemia (AML) who were ineligible for standard induction chemotherapy.
Poster Sessions on June 4 gave an in-depth look at data from the KEYNOTE-183 and KEYNOTE-185 trials, which were halted nearly a year ago due to increased risk of death for patients with multiple myeloma who were being treated with the drug combination.
Treatment with the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) induced durable, high response rates in patients with refractory diffuse large B-cell lymphoma (DLBCL), according to results from the ZUMA-1 trial (Abstract 3003).
A chemotherapy-free combination immunotherapy regimen had similar efficacy as the standard chemotherapy regimen in patients with previously untreated, advanced follicular lymphoma in the phase III RELEVANCE trial (Abstract 7500).
Adding nelarabine to chemotherapy improved 4-year disease-free survival (DFS) and provided an overall survival (OS) of 90% in patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL), according to results from the largest phase III clinical trial to date.
The combination of ibrutinib and rituximab significantly improved progression-free survival (PFS) and response rates compared to placebo plus rituximab in patients with Waldenström’s macroglobulinemia (WM).
Patients with relapsed or refractory multiple myeloma treated with once-weekly carfilzomib had a higher response rate than patients treated with the twice-weekly regimen in the ARROW study, introducing the potential for more convenient dosing for patients.